Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 14 of 14 for “"Exenatide"”.
-
Physiology and pharmacology of diabetes therapies in the cat: insulin detemir, insulin glargine, exenatide and the incretin effect
… study the pharmacodynamics of the GLP-1 mimetic, exenatide. An exenatide-specific ELISA was used for evaluation of exenatide pharmacokinetics. Finally, we studied the incretin effect in cats and compared the effect of glucose, lipids or amino acids on secretion of the incretin hormones …
-
Physiological, Morphological and molecular biological studies of the effect of Glucagon-like peptide-1 and exenatide in the diabetic rat pancreas
… peptide-1 (GLP-1) and its synthetic agonist, exenatide on the diabetic rat pancreas compared to healthy, agematched controls. These incretins exert their beneficial effects by repairing the pancreatic islets. Thus, increasing pancreatic beta (β) cell mass and in turn it will help to synthesize …
-
A 4-month randomized controlled clinical trial of adjuvant exenatide or pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control
… effects of 16 weeks of treatment with adjuvant Exenatide or Pramlintide versus insulin alone on glycemic control, as measured by glycated hemoglobin (HbA1C) and 1,5-Anhydroglucitol (1,5-AG), or GlycoMark, in pediatric Type 1 Diabetes Mellitus (T1DM). We present here the preliminary results …
-
GLP1R IS A T CELL NEGATIVE COSTIMULATORY MOLECULE
… the treatment with the GLP1R agonist Exenatide significantly prolonged cardiac and islet allograft survival and reduced graft T lymphocytes infiltrate. Interestingly, a strong synergism in mitigating alloimmunity was observed between Exenatide and Rapamycin. Mechanistically, mitogen …
-
Investigation of cell-based therapies employing microcapsules and microspheres: encapsulation and controlled release
… we encapsulated porcine islets together with exenatide-loaded poly(latic-co-glycolic acid) MSs to enhance islet survival and function as exenatide locally released in the intracapsular environment. The MCs with exenatide-loaded MSs showed improved glucose-stimulated response. The results …
-
The Development of Methods for Generating Fc-Conjugates and Antibody-Drug Conjugates
… and/or a fluorophore or a cytotoxic drug. An Fc-Exenatide conjugate was synthesised and demonstrated good biological activity in a cell-based potency assay. The Fc-Exenatide conjugate was also evaluated in an in vivo PK study and exhibited a long circulation half-life (27-35 hours) compared to …
-
Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans
… the non-invasive haemodynamic effects of exenatide (a licensed GLP-1 receptor agonist), glucagon and exenatide:glucagon dual agonism in healthy male adults. Consistent with its well-known chronotropic effect, high dose glucagon acutely increased heart rate by ~11 bpm after 120 minutes …
-
Heterologous production of recombinant peptidylglycine α-amidating monooxygenase for the production of biosimilar α-amidated peptides
… of the peptide pharmaceutical precursor for exenatide into its final bioactive form.
-
Coronary artery disease in metabolic syndrome: a role for the sarcoplasmic reticulum Ca2+ ATPase
… peptide-1 (GLP-1) receptor agonist, exenatide, increased SERCA function. However, in vivo treatment of Ossabaw swine with MetS with the GLP-1 receptor agonist, AC3174, had no effect on CAD progression and in vitro examination revealed resistance of SERCA to GLP-1 receptor agonism in …
-
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells
… Lixisenatide, Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently used to treat diabetes, may also be beneficial in the treatment of neurodegenerative conditions such as AD, as they have been shown to exert neuroprotective properties. Research has also suggested that one of these …
-
Development of New Synthetic Approaches to Biologically-Active Peptides
… and purification of the diabetes peptide exenatide (39 amino acids), without making use of preparative-HPLC. An attempt was made to extend this methodology to the synthesis of cyclic thioether peptides; however, this did not provide conclusive results. An alternative approach to cyclising …
-
Characterisation and pharmacological regulation of GLP-1-mediated glucose homeostasis
… glucose level, GLP-1-based treatments, such as exenatide and liraglutide, have been widely used in T2DM patients. However, in contrast to the well-studied phenomenon of how GLP-1 enhances GSIS, the mechanism of how GLP-1 regulates glucagon secretion is still unclear. Therefore, the aim of this …
-
Η επίδραση της παρστατίνης 1-26 στη μυοκαρδιακή βλάβη από ισχαιμία και επαναιμάτωση : μελέτη σε πειραματικό μοντέλο κονίκλων
Έχει αποδειχθεί ότι η εξενατίδη και η κυκλοσπορίνη προστατεύουν μερικώς τον περιορισμό της μυοκαρδιακής ιστικής βλάβης μετά από επαναιμάτωση. Στη παρούσα διατριβή προτείνεται ο συνδυασμός περισσοτέρων του ενός καρδιοπροστατευτικών παραγόντων, που στοχεύουν σε περισσότερους φαρμακολογικούς στόχους, …
-
Uso de medicación con efecto incretina para control glucémico en pacientes adultos hospitalizados con diabetes mellitus tipo 2 entre 2002 y 2018
Introducción: La diabetes mellitus tipo 2 es una enfermedad con alta prevalencia a nivel mundial y su incidencia aumenta a medida que pasan los años, por lo que es frecuente que los pacientes que se encuentran hospitalizados por diversas causas tengan diabetes como antecedente. En este grupo …